Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Syndax Pharmaceuticals, Inc.

SNDX

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

Last trade $9.34
Day change +$0.21 (+2.30%)
Day range $9.04 – $9.49
Volume 1,151,730
Market cap $822M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$821.96M
Price / earnings
—
Price / book
-47.84×
Price / sales
2.84×
EV / sales
3.21×
EV / EBITDA
-5.6×

Profitability

Earnings per share
-$2.33
Return on assets
-30.24%
Return on equity
1,219.34%
Dividend yield
0%

Liquidity and leverage

Debt / equity
-14.25×
Current ratio
4.69×
Quick ratio
4.37×
Cash ratio
1.12×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$177.55M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for SNDX, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$83.3M$72.79M$64.86M$68.73M$45.87M$37.96M$20.04M$7.68M
Cost of revenue$14M$3.21M$2.63M$2.71M$2.1M$1.28M$885K$826K
Gross profit$69.3M$69.58M$62.23M$66.02M$43.77M$36.68M$19.16M$6.85M
Selling, general and administrative$43.72M$41.54M$37.59M$49.93M$44.92M$43.81M$41.03M$37.69M
Research and development$67.48M$68.04M$58.85M$78.64M$56.28M$62.23M$61.64M$65.53M
Total operating expenses$111.2M$109.58M$108.28M$104.38M$101.2M$106.03M$110.96M$103.22M
Operating income-$41.9M-$40M-$46.05M-$38.36M-$57.43M-$69.35M-$91.81M-$96.37M
Interest expense-$1.17M-$12.68M$0$0$0-$7.86M-$2K$124K
Income before taxes-$49.43M-$49.36M-$42.67M-$68.01M-$60.72M-$71.85M-$84.85M-$94.17M
Income taxes$0$0$0$0$0$0$0$0
Net income-$49.43M-$49.36M-$42.67M-$68.01M-$60.72M-$71.85M-$84.85M-$94.17M
Net income attributable to common shareholders-$49.43M-$49.36M-$42.67M-$68.01M-$60.72M-$71.85M-$84.85M-$94.17M
EBITDA-$41.89M-$39.99M-$46.04M-$38.36M-$57.42M-$69.35M-$91.56M-$96.37M
Basic earnings per share-$0.55-$0.55-$0.48-$0.78-$0.70-$0.83-$0.98-$1.09
Diluted earnings per share-$0.55-$0.55-$0.48-$0.78-$0.70-$0.83-$0.98-$1.09

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Syndax Pharmaceuticals (SNDX) Reports Q3 Loss, Beats Revenue Estimates

Syndax Pharmaceuticals reported a Q3 loss of $0.55 per share, missing EPS expectations by 5.77%, though it beat revenue estimates with $83.3 million (up 81.5% year-over-year). The stock has underperformed the market by 45.7% year-to-date and carries a Zacks Rank #3 (Hold) rating with mixed estimate revisions.

GlobeNewswire Inc.

Syndax Announces Participation in November Investor Conferences

Syndax Pharmaceuticals announced that CEO Michael A. Metzger and management team members will participate in four major investor conferences in November 2026, including events hosted by Guggenheim, Stifel, UBS, and Jefferies. Live webcasts of the fireside chats will be available on the company's website.

Zacks Investment Research

Earnings Preview: Niagen Bioscience (NAGE) Q3 Earnings Expected to Decline

Niagen Bioscience is expected to report Q3 2026 earnings on November 4 with a projected loss of $0.01 per share and revenues declining 11.3% year-over-year to $30.15 million. The company has a negative Earnings ESP of -500% and Zacks Rank #4, making it unlikely to beat consensus estimates. The stock does not appear to be a compelling earnings-beat candidate.

Zacks Investment Research

Syndax Pharmaceuticals (SNDX) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Syndax Pharmaceuticals is expected to report a quarterly loss of $0.52 per share for Q3 2026, representing a 25.7% year-over-year increase in losses, though revenues are projected to grow 76.8% to $81.09 million. With a negative Earnings ESP of -2.91% and a Zacks Rank #3 (Hold), the stock is not considered a compelling earnings-beat candidate. The company has a mixed track record, beating consensus estimates in only 2 of the last 4 quarters.

GlobeNewswire Inc.

Syndax to Announce Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 2, 2026

Syndax Pharmaceuticals announced it will report Q3 2026 financial results and host a conference call on November 2, 2026. The company is a commercial-stage biopharmaceutical firm with FDA-approved cancer therapies including Revuforj® (revumenib), a menin inhibitor, and Niktimvo™ (axatilimab-csfr), a CSF-1 receptor blocking monoclonal antibody.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.